Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Monitoring Guidelines for Immunomodulatory Drug Therapy in Dermatology
Description
The presentation discusses monitoring guidelines for patients undergoing immunomodulatory drug therapy in dermatology, particularly for conditions like psoriasis. The speaker, from the University of Kansas, highlights the importance of thorough patient evaluation, illustrated by a case study of a 38-year-old man with a longstanding rash and significant weight loss. Key screening recommendations include conducting a comprehensive metabolic panel to assess overall health, monitoring for HIV and hepatitis infections, and screening for latent tuberculosis before initiating biologics. The speaker suggests tailoring monitoring practices based on individual patient risk factors and adherence to guidelines from authoritative bodies like the American Academy of Dermatology and the National Psoriasis Foundation. They emphasize that patients on biologics who are at risk for infections should have appropriate vaccinations and follow-up testing, including regular assessments of liver function for those with a history of hepatitis. The guidelines also advise against the use of specific biologics in patients with certain conditions, such as heart failure and inflammatory bowel disease, and promote interdisciplinary collaboration with specialists in infectious disease and hepatology as necessary. The talk concludes with a summary of routine monitoring and the importance of preventive measures in managing patients on immunosuppressive therapies.
View moreConclusions
- Biologics used for psoriasis require careful patient evaluation before initiation.
- General screening for health issues like infections, inflammation, and metabolic function is crucial before starting biologics.
- HIV screening is recommended based on individual risk factors and should involve follow-up care with specialists.
- Hepatitis screening is essential to prevent reactivation or progression in immunosuppressed patients.
- Risk stratification for hepatitis B and C infections is recommended prior to biologic therapy initiation.
- Latent tuberculosis (TB) screening is necessary, along with annual follow-ups for high-risk patients.
- The use of IL-17 and IL-23 inhibitors in patients with latent TB is considered safe and preferred over TNF antagonists.
- Endemic mycosis screening is advised in symptomatic patients with risk factors, despite lack of specific guidelines from the AAD.
- Monitoring for heart failure, inflammatory bowel disease, and malignancy is recommended to avoid severe complications.
- A structured approach to patient screening and follow-up enhances patient safety and therapy effectiveness.
- Menter et al. JAAD. J Am Acad Dermatol 2019;80:1029-72.
- Doherty et al. JAAD. 2008 Aug; 59(2):209-17.
- Esteban Dauden et al. American Journal of Clinical Dermatology (2024) 25:333-342. https://doi.org/10.1007/s40257-024-00845-4
- Galgiani et al. J. Clin Infect Disease 2016 Sep 15;63(6):e112-46
- Chirch et al. JAAD 2014;71:11.e1-7